Objective. To explore the causal relationship between gout and Type 2 diabetes based on genetic evidence and national outpatient database.
Introduction
Gout is frequently associated with various kinds of comorbidities, such as hypertension, chronic kidney disease and hyperlipidaemia, which complicate management and affect long-term prognosis [1, 2] . In addition, insulin resistance and Type 2 diabetes have also been noted to be associated with gout. Yoo et al. [3] reported that the incidence of insulin resistance in gout patients increased by as much as 35% over individuals without gout, and Suppiah et al.
[4] demonstrated a high prevalence of gout in patients with Type 2 diabetes, whereas Rodriguez et al. [5] suggested that patients with diabetes were at a lower future risk of gout independent of other risk factors. Furthermore, some studies have even shown strong associations between gout and metabolic syndrome [610] as well as cardiovascular disease [11, 12] . Whether the onset of Type 2 diabetes exacerbates the future risk for developing gout or vice versa has not been well studied.
The metabolic syndrome, obesity, alcohol consumption, lead exposure as well as age and male gender have been shown to associate with gout [1316] . Meanwhile, the genetic component findings are related to hyperuricaemia [1721] as well as function of pro-inflammatory cytokines, such as TNF-gene [22] , cyclic GMP-dependent protein kinase II gene [23] and TGF-1 gene [24] . The contributions of the associated genetic factors to gout are various, and some diseases may share the common genetic components with gout. Thus, it is important to clarify the relationship between comorbid diseases and gout based on genetic evidence.
The purpose of our study was to explore the diseases that shared the most genetic markers with gout by a genome-wide association study (GWAS), and conducted an analysis of standardized incidence ratio (SIR) from the outpatient database to reveal the incidence risks between gout and comorbid diseases in the general population.
Materials and methods

Study design
We designed this study in three stages: (i) screening genetic risk markers for gout by a GWAS; (ii) exploring the comorbid diseases with gout based on genetic component by applying the genetic risk markers to MetaCore platform; and (iii) confirming the associations by analysis with the national outpatient records released from National Health Research Institute (NHRI) in Taiwan.
GWAS
The participants included in GWAS were divided into case and control groups. The case group was 20 male gout patients, who were enrolled under the following criteria: with primary gout, non-Taiwan indigenous ancestry, at least father or brother with gout history, age 440 years at first gout attack, without a habit of alcohol consumption behaviour and BMI <27 kg/m 2 before first gout attack.
The gout patients were diagnosed by a rheumatologist in the hospital, and were enrolled after giving their informed consent to Kaohsiung Chang-Gung Memorial Hospital in 2010. Genomic DNA was applied to the Illumina Human660W-Duad BeadChip (Illumina, Inc., San Diego, CA, USA) for whole-genome genotyping. Single nucleotide polymorphisms (SNPs) were excluded if: (i) the SNP was not matched with the controls; (ii) the SNP had missing data from any one of the cases; and (ii) there was significant distortion from HardyWeinberg equilibrium in the controls (P < 10 À7 ). The chip for GWAS revealed 592 652 SNPs, and a total of 479 403 SNPs were effective for further analysis after excluding those that did not meet the above criteria.
National outpatient database
The outpatient database was released from the NHRI in Taiwan, which provided us with one million random subjects covering the years 19972008 for the study. The data sets contain outpatient records and prescription details, including the gender, three diagnosed codes (CD-9-CM) and each prescription. We also obtained the approval of the Institute Review Board of Kaohsiung Medical University for analysis of the database for research (KMUH-IRB-20110130).
The cumulative incidence of Type 2 diabetes or gout were revealed by analysis of the outpatient database. The authors defined those male patients with or without gout diagnosed during the period from 1997 to 2000 as the first baseline population, whose age was >20 years, and who had no diagnosis of outcome disease; and then we analysed the records to find incident Type 2 diabetes from 2001 to 2008. Inversely, second baseline population was selected to reveal an incident gout among Type 2 diabetes patients during the same time period. At enrolment, no patients were diagnosed with cancer. The controls were selected by matching the age groups of cases on a ratio of 5 : 1. Gout was identified by diagnosis with ICD-9 code 274 and prescription of any of the following drugs more than three times: colchicine, allopurinol, benzbromarone, probenecid and sulphinpyrazone. Type 2 diabetes was diagnosed by ICD-9 code 250 more than three times after excluding Type 1 diabetes codes (250.x1, 250.x3), whereas cancer was diagnosed by the ICD-9 code from 140 to 208, and those not diagnosed by ICD-9 codes 274 and 250 were classified as gout-and diabetes-free patients, respectively.
Statistics
The association analysis in GWAS was carried out by chi-square test to compare allele frequency and genotype distribution between cases and controls using four single-point methods for each SNP: genotype, allele, dominant and recessive models. The most significant statistical result was chosen from the four models. The alpha level was 10 À7 after adjustment of Bonferroni correction. SNPs with P-values less than alpha level were considered to be significantly associated with the traits, and these were then applied to MetaCore platform (version 6.6; http://portal.genego.com) to explore the comorbid diseases with gout. The incidence of comorbid disease per 1000 person-months was estimated among those with or without gout (or Type 2 diabetes), and age-adjusted SIR and 95% CI were estimated to show the rate ratio of incident disease among these two groups [25] . We performed the statistical analysis for GWAS by SAS program (v9.2), and the national outpatient records by PERL (v5.8) program.
Results
Twenty male gout patients were selected for GWAS, the participants' mean (S.D.) ages at enrolment and at gout onset were 41.75 (7.79) and 26.70 (7.32) years, respectively. A total of 334 SNPs were found to be significantly related to gout by GWAS (all P < 10 À7 ), and then these SNPs were applied to MetaCore platform. The results displayed the most significantly related disease was Type 2 diabetes as recognized by 36 gene symbols (Table 1) . Even when we increased the alpha level to 10 À3 , a total of 921 SNPs were found to have significant associations between gout patients and controls, and the result also showed that Type 2 diabetes was the most significant disease related to gout as recognized by 74 gene symbols (data not shown).
The first baseline population included 9022 male gout patients and 45 110 male controls aged >20 years and without diagnosis of Type 2 diabetes or cancer. The mean (S.D.) age of the gout patients was 51.75 (14.60) years and the controls was 51.64 (15.03) years (Table 2) , while the means of follow-up were 7.53 and 8.38 years for gout patients and controls, respectively. The overall incident Type 2 diabetes were 1.50 and 0.57 cases per 1000 person-months among those diagnosed with and without gout, respectively. The SIR was 2.59 (95% CI 2.42, 2.78) after adjustment of age (Table 2) . Concerning the second baseline population, the mean (S.D.) age of those with Type 2 diabetes was 57.66 (11.55) years (n = 8078) and the controls was 57.47 (12.07) years (n = 40 390), while the means of follow-up were 7.92 years for Type 2 diabetes and 7.86 years for controls. The overall incident gout was 1.06 and 0.64 cases per 1000 person-months among those diagnosed with and without Type 2 diabetes, respectively. The age-adjusted SIR was estimated to be 1.61 (95% CI 1.48, 1.74; Table 2 ).
Discussion
Our study suggests that gout and Type 2 diabetes share the common genetic markers identified by the GWAS most, and that there existed a mutually inter-dependent effect on increased incidences confirmed by analysis of the national outpatient clinical records. Although the incident association between gout and Type 2 diabetes has not been defined clearly before, here we suggest, based on genetic and clinical evidence, that gout showed a most significant association with incident Type 2 diabetes, and vice versa. The gout patients who participated in the GWAS tended to have genetic causal factors such as those with gout family history, age <40 years as well as no alcohol consumption habit or obesity at the time of first gout attack. The above criteria ensure this study explored the genetic factors related to gout and that they would not have been confounded by environmental factors such as alcohol consumption and obesity.
Although Type 2 diabetes showed an association with gout, obesity and insulin resistance may represent important links between them. Some studies even A total of 334 SNPs were found to be significantly associated with gout in the GWAS: after applying the SNPs to MetaCore platform, it was found that the listed 36 genes were shared by Type 2 diabetes.
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showed that increased body weight is associated with higher serum urate levels and an increased risk of gout [2628] , and obesity also leads to insulin resistance, which in turn results in enhanced risk for the development of Type 2 diabetes [29] . However, all the patients included in our study in the GWAS had not been obese before the first gout attack, so we do not consider obesity to be the risk factor for the association of Type 2 diabetes in this study. The authors found that Type 2 diabetes was comorbid with gout on the basis of genetic evidence instead of environmental evidence; the following results also showed a similar effect, i.e. that there was a higher incidence of Type 2 diabetes among gout patients than the incidence of gout among Type 2 diabetes patients. The molecular aetiologies of Type 2 diabetes are diverse, which results in reduced beta-cell mass, disruptions of beta-cell function as well as lipid profile metabolism. Our study showed 36 genes for the risk of both gout and Type 2 diabetes, including carboxypeptidase E (CPE), which is a major link between hyperlipidaemia and beta-cell death pathways in diabetes [30] ; and its variants resulting in altered CPE activity have been reported in patients with early-onset Type 2 diabetes [31] . Other variants in ATP-binding cassette (ABCC8) genes were shown to be associated with the regulation of insulin secretion, and they were suggested to be diabetes susceptibility genes [32, 33] . Genetic variation in the solute carrier (SLC22A1) gene has found a glucoselowering effect by reducing glycated haemoglobin (HbA1c) level in diabetes patients [34] . Alterations in Wnt signalling might also be involved in the pathogenesis of diabetes, which influences endocrine pancreas development and modulates mature beta-cell functions including insulin secretion; variants in the WNT5B gene were also found to be strongly associated with Type 2 diabetes [35, 36] .
Moreover, evidence shows that hyperlipoproteinaemia is significantly associated both with gout and Type 2 diabetes [3739] . In our study, the ATP-binding cassette genes (ABCA1 and ABCG1) were found to be associated with gout and Type 2 diabetes, functioning as a cholesterol efflux pump in the cellular lipid removal pathway [40, 41] ; and some studies revealed that cholesterol regulates the function and survival of beta cells [42, 43] . Epidemiological studies also showed that low highdensity lipoprotein cholesterol, low low-density lipoprotein cholesterol and hypertriglyceridaemia precede the diabetic manifestation and are independent risk factors for developing Type 2 diabetes [39, 44] , and they have also been shown to be associated with ABCA1 or ABCG1 gene functions in mice [43] .
In conclusion, this study excludes gender and environmental confounding factors, such as obesity and alcohol consumption, and, based on genetic evidence and clinical outpatient data, it shows that both gout and Type 2 diabetes share most of the common genetic risk factors, and that there exists a mutually interdependent effect on higher incidences between these two diseases. The baseline population was selected from those diagnosed with target disease after excluding those with outcome and cancer during 19972000. The controls were selected from those without diagnosis of outcome and cancer and by matching to those ages with target disease on a ratio of 5 : 1. The baseline populations were follow-ups during 20012008 to find the outcome disease.
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